InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Monday, 09/30/2019 12:50:28 PM

Monday, September 30, 2019 12:50:28 PM

Post# of 3443
News: $IDRA Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1 (...

In case you are interested IDRA - Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors